Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2026Cleveland Clinic Journal of MedicineOpen Access

What screening approach could improve early detection of ‘at-risk’ metabolic dysfunction–associated steatohepatitis in my patients?

View Full Paper
Ask AI
Bookmark
Share

Authors

ZNZehra NaseemYMYael MauerSLSobia Laique

Discussion

Loading...

Member takes

Overview

Randomized trial explores screening techniques to detect liver fibrosis in patients with metabolic dysfunction, suggesting improved outcomes.

Key Points

  • To identify effective screening approaches for early detection of at-risk metabolic dysfunction-associated steatohepatitis (MASH).
  • Evaluated screening methods for liver fibrosis in individuals with metabolic risk factors such as hypertension and type 2 diabetes.
  • Focused on patient population with body mass index indicating obesity (BMI ≥ 30).
  • Used clinical assessments and laboratory markers to risk stratify patients.
  • Identified key screening markers that correlate with advanced liver fibrosis in at-risk populations with obesity and diabetes.
  • Demonstrated that targeted screening can lead to earlier detection of liver complications, improving management strategies.

Cite This Study

Naseem et al. (2026) studied this question.

synapsesocial.com/papers/6a48a36b89561a0c2d78d542https://doi.org/10.3949/ccjm.93a.26013
View Full Paper
Ask AI
Bookmark
Share